November 15, 2019 10:21 AM ESTUpdated 05:59 PM
R&D
FDA+

Five drugs, in­clud­ing two No­var­tis ther­a­pies, win EMA en­dorse­ment

Natalie Grover

Reporter

As is cus­tom, an EMA pan­el on Fri­day is­sued its week­ly rec­om­men­da­tions on mar­ket­ing ap­pli­ca­tions sub­mit­ted by drug de­vel­op­ers. This week, the agency backed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times